BOSTON, Nov. 12,
2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA),
which is building the leading platform for cell programming and
biosecurity, today announced the completion of the first milestone
of a previously announced partnership with Merck, known as MSD
outside of the United States and
Canada, focused on improving
biologic manufacturing. As part of this milestone completion,
Ginkgo will receive a research milestone payment of $9 million in cash.
The two companies will now move on to the second stage of this
partnership, which will be focused on continuing to improve the
production process.
"We're excited to achieve the first milestone of our
collaboration with Merck and continue our work to improve biologic
manufacturing production," said Jason
Kelly, CEO and co-founder, Ginkgo Bioworks. "It's very
meaningful when our team can drive impactful and technically
innovative work like this, especially when we're working
shoulder-to-shoulder with counterparts like the team at Merck. As
we go into the next phase of this project, we'll continue to deploy
the strain engineering, high-throughput screening and process
development capabilities, as well as the assets and know-how that
make Ginkgo a unique and powerful partner to top pharmaceutical
companies."
To learn more about how you can improve your biologic
manufacturing processes, visit Ginkgo Protein Expression
Services.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell
programming, providing flexible, end-to-end services that solve
challenges for organizations across diverse markets, from food and
agriculture to pharmaceuticals to industrial and specialty
chemicals. Ginkgo Biosecurity is building and deploying the
next-generation infrastructure and technologies that global leaders
need to predict, detect, and respond to a wide variety of
biological threats. For more information,
visit ginkgobioworks.com and ginkgobiosecurity.com, read
our blog, or follow us on social media channels such as X
(@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads
(@GinkgoBioworks), or LinkedIn.
GINKGO BIOWORKS INVESTOR
CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA
CONTACT:
press@ginkgobioworks.com
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding the capabilities and potential success of the
partnership and Ginkgo's cell programming platform. These
forward-looking statements generally are identified by the words
"believe," "can," "project," "potential," "expect," "anticipate,"
"estimate," "intend," "strategy," "future," "opportunity," "plan,"
"may," "should," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) volatility in the price of Ginkgo's securities due
to a variety of factors, including changes in the competitive and
highly regulated industries in which Ginkgo operates and plans to
operate, variations in performance across competitors, and changes
in laws and regulations affecting Ginkgo's business, (ii) the
ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional business
opportunities, (iii) the risk of downturns in demand for products
using synthetic biology, (iv) the uncertainty regarding the demand
for passive monitoring programs and biosecurity services, (v)
changes to the biosecurity industry, including due to advancements
in technology, emerging competition and evolution in industry
demands, standards and regulations, (vi) the outcome of any pending
or potential legal proceedings against Ginkgo, (vii) our ability to
realize the expected benefits from and the success of our Foundry
platform programs, (viii) our ability to successfully develop
engineered cells, bioprocesses, data packages or other
deliverables, and (ix) the product development or commercialization
success of our customers. The foregoing list of factors is not
exhaustive. You should carefully consider the foregoing factors and
the other risks and uncertainties described in the "Risk Factors"
section of Ginkgo's annual report on Form 10-K filed with the U.S.
Securities and Exchange Commission (the "SEC") on February 29, 2024, Ginkgo's most recent quarterly
report on Form 10-Q, and other documents filed by Ginkgo from time
to time with the SEC. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Ginkgo assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Ginkgo does not give any assurance
that it will achieve its expectations.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-advances-collaboration-with-merck-to-improve-biologics-manufacturing-302301872.html
SOURCE Ginkgo Bioworks